D3-conjugated gemcitabine liposomes

D3-conjugated gemcitabine liposomes, referred to as D3-LNP-GEM in preclinical studies, are an investigational targeted therapy for mesothelin (MSLN)-expressing cancers, particularly pancreatic adenocarcinoma. The platform consists of liposomal nanoparticles (LNP) loaded with the chemotherapy drug gemcitabine, surface-conjugated with a high-affinity anti-MSLN nanobody (D3 Nb). The D3 Nb enables selective targeting of MSLN-positive cancer cells, enhancing tumor-specific delivery and minimizing off-target effects. In preclinical models, D3-LNP-GEM demonstrated superior cytotoxicity, tumor accumulation, and antitumor efficacy compared to non-targeted gemcitabine liposomes, including significant tumor regression and prolonged survival in pancreatic adenocarcinoma xenografts. The therapy also downregulates key oncogenic drivers (FN1 and TWIST1) and inhibits pro-survival signaling (AKT/NF-κB pathway), supporting its potential as a precision oncology agent. No significant toxicity was observed in animal studies, suggesting favorable biocompatibility[1].